Professor Brian Blagg earned a B.A. in chemistry and environmental studies in 1994 from Sonoma State University and a Ph.D. in organic chemistry in 1999 from the University of Utah. In 2002, Blagg completed an NIH Postdoctoral Fellow at The Scripps Research Institute.
- Design, synthesis, and evaluation of Hsp90 inhibitors as anti-cancer agents
- Biological characterization of Hsp90 inhibitors against colon, breast, and prostate cancers
- Development of novel chaperone inhibitors/regulators for the treatment of neurodegenerative diseases
- Development of assays for characterization of Hsp90 inhibitors
The primary goals of the Blagg Research Team are to design, synthesize, and evaluate novel inhibitors of the Hsp90 protein folding process. To achieve these goals, they use computer modeling to design new molecules to bind to these ATP binding sites, develop new organic reactions that allow access the desired compounds in a highly efficient manner, and finally, develop assays that are suitable for determining the biological effects of our rationally designed Hsp90 inhibitors. They are engaged in more than 30 collaborative studies with researchers throughout the world.